Positron Emission Tomography Imaging With [¹⁸F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes

Adam Fleisher, Michael J. Pontecorvo, Michael D. Devous, +27

JAMA Neurology

Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density

Craig Curtis, José E. Gámez, Upinder Singh, +26

JAMA Neurology

ABBY

Jeffrey L. Cummings, Sharon Cohen, Christopher H. van Dyck, +13

Neurology

Targeting Prodromal Alzheimer Disease With Avagacestat

Vladimir Coric, Stephen Salloway, Christopher H. van Dyck, +25

JAMA Neurology

Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial

Daniel K. Burns, Robert Alexander, Kathleen A. Welsh‐Bohmer, +132

The Lancet Neurology

Neurodegenerative DiseasesNeuropsychologyAlzheimer's DiseaseDementiaVascular Dementia +9

Performance of [¹⁸F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA‐AA recommendations for the neuropathologic diagnosis of Alzheimer's disease

Stephen Salloway, José E. Gámez, Upinder Singh, +24

Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring

A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant

Judith Falloon, Fei Ji, Craig Curtis, +8

Vaccine

Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease

Ming‐Chi Lu, Michael J. Pontecorvo, Michael D. Devous, +14

JAMA Neurology

Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses

Judith Falloon, H. Keipp Talbot, Craig Curtis, +9

Clinical and Vaccine Immunology

Respiratory Virus ImmunityImmunologyImmunodominanceFlu VaccinationInfluenza Vaccines +17

Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment

Erik Mogalian, Diana M. Brainard, Anu Osinusi, +9

Clinical Pharmacokinetics

Hepatic DisordersHepatologyLiver PhysiologyHepatic ImpairmentVirology +5